Respiratory failure associated with the lipodystrophy syndrome in an HIV-positive patient with compromised lung function

Natasha Press MD FRCPC¹, Valentina Montessori MD FRCPC¹, Tony R Bai MD FRCPC², Julio Montaner MD FRCP³

Divisions of ¹Infectious Diseases and ²Respirology, St Paul’s Hospital, University of British Columbia; ³BC Centre for Excellence in HIV and AIDS, St Paul’s Hospital, Vancouver, British Columbia

The use of highly active antiretroviral therapy (three drugs or more) has led to a decrease in human immunodeficiency virus (HIV)-related morbidity and mortality compared with patients taking only mono- or dual therapy. Protease inhibitors are recommended as a component of this combination therapy, and have been shown to provide both...

Correspondence: Dr Natasha Press, Division of Infectious Diseases, St Paul’s Hospital, 667-1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6. Telephone 604-806-8642, fax 604-806-8527, e-mail npress@hivnet.ubc.ca
virological and clinical benefits, such as a decreased rate of opportunistic infections and acquired immunodeficiency syndrome (AIDS)-related deaths (1). However, use of protease inhibitors is associated with morphological and metabolic alterations including peripheral lipodystrophy, central adiposity, breast hypertrophy, hyperlipidemia and insulin resistance. These alterations are referred to collectively as the lipodystrophy syndrome, but can be divided into lipoatrophy (subcutaneous fat loss in limbs, glutei and face), lipoaccumulation (buffalo hump, bull neck, abdominal adiposity), mixed lipoatrophy and lipoaccumulation, and metabolic abnormalities (hyperglycemia, hypertriglyceridemia, hypercholesterolemia) (2). Previous studies have reported rates of protease inhibitor-induced lipodystrophy syndrome as high as 85%. However, severe lipodystrophy is seen in 10% to 15% of patients after several years of treatment (3).

We present an HIV-positive patient with chronic obstructive pulmonary disease (COPD) who developed the lipodystrophy syndrome associated with protease inhibitors. We speculate that his central adiposity and lipodystrophy further compromised his lung function, leading to respiratory failure and death.

**CASE PRESENTATION**

In 1994, a 41-year-old man presented with *Pneumocystis carinii* pneumonia (PCP). He was found to be HIV-positive (ELISA and Western blot) and had a CD4 count of 40 cells/μL...
at presentation. He had a history of previous injection drug use, multiple female sexual partners and a tattoo. He was started on dual antiretroviral therapy, and when protease inhibitors became available in 1996, he was changed to a triple regimen including a protease inhibitor. His plasma viral load decreased to undetectable levels (fewer than 400 copies/mL), but by 1998, the viral load had increased to 500,000 copies/mL. His regimen was altered, and he responded with an increase in CD4 cell count to 680 and an undetectable viral load (fewer than 50 copies/mL) (Figure 1).

From 1994 to 1998, his opportunistic infections included PCP, mycobacterial adenitis (smear-positive, culture-negative), multidermatomal herpes zoster, HIV retinopathy and recurrent bacterial pneumonias.

Following his episode of PCP in 1994, he developed progressive shortness of breath. He was a smoker with a 25 pack-year history. Previous occupational exposures included working in a sawmill and spray painting cars. He had two pet dogs but no bird exposure and no history of foreign travel. Although he had a history of injection drug use, he had never injected particulate matter, such as crushed pills. Although he had previous mycobacterial adenitis, his chest x-ray showed no evidence of pulmonary involvement. Pulmonary function tests (March 1996) revealed severe airflow obstruction (forced expiratory volume in 1 s 29% predicted, 15% improvement with bronchodilator use) with marked hyperinflation (residual volume 226% predicted) and a severe reduction in diffusion (39% predicted). Expiratory reserve volume was markedly reduced. There was a significant response to bronchodilator. The patient was diagnosed with COPD with partial reversibility secondary to smoking, PCP, and possibly HIV infection (4) and injection drug use (5). Beginning in 1995, he was treated with inhaled corticosteroids, salbutamol, ipratropium and, later, salmeterol.

In June 1998, he had been noted to have lipodystrophy syndrome. He had abdominal obesity with striae, a buffalo hump and muscle wasting of his limbs (Figure 2). He had previously had only one short course of prednisone for a COPD exacerbation and was not thought to be cushingoid. Over the next year, his lipodystrophy worsened, as did his respiratory symptoms. By 1999, he was confined to a wheelchair and required home oxygen therapy. His arterial blood gases showed chronic respiratory acidosis with carbon dioxide retention (pH 7.38, PCO₂ 52, bicarbonate 31). A high resolution computed tomography scan of his chest (March 1999) showed confluent centrilobular emphysema, which was more severe in the upper lobes. In addition, there was increased adiposity in the mediastinum and upper anterior chest, thought to be a component of his lipodystrophy syndrome. In May 1999, all of his antiretroviral medications were stopped. It was thought that his thorax and abdominal obesity and muscle wasting might have been contributing to his worsening respiratory status, and that by stopping his antiretroviral medications, his pulmonary function would improve.

On May 14, 1999, he presented to hospital with confusion and respiratory distress, and was found to have hypercapnic hypoxemic respiratory failure (pH 7.30, PCO₂ 60, PO₂ 45, bicarbonate 29). He required intensive care unit admission, intubation and ventilation. He was unable to be weaned from the ventilator despite multiple attempts. After 14 days in hospital, he developed a nosocomial pneumonia, and, despite aggressive care, he died.
DISCUSSION

Although our patient had significant obstructive pulmonary disease causing morbidity and, ultimately, his death, we speculate that the lipodystrophy syndrome contributed to his outcome by increasing his abdominal girth, and causing adiposity of his mediastinum and upper chest. A dramatic worsening over a relatively short time in the severity of his respiratory symptoms coincided with the worsening lipodystrophy.

Increasing abdominal and thoracic fat compromise pulmonary function by several mechanisms including increasing the work of breathing, compromising respiratory muscle function, promoting small airway closure and increasing the risk of the development of obstructive sleep apnea/hypventilation syndromes (6). Computed tomography has been used to provide a direct measurement of thoracic and abdominal fat, but the analysis of results is not well standardized. Patients with the lipodystrophy syndrome have an increased ratio of visceral adipose tissue to total adipose tissue when computed tomography scans are done at the level of the fourth lumbar vertebra. However, thoracic adiposity is not defined in this population (7).

Attempts to identify patients who are more likely to develop lipodystrophy are ongoing. Risk factors may include a longer duration of protease inhibitor therapy, and the combination therapy of ritonavir-saquinavir rather than indinavir alone (8). There appears to be no association between lipodystrophy and CD4 count, viral load, duration of HIV infection, other concomitant therapies or previous AIDS (9). The pathogenesis of the development of lipodystrophy is not well understood. It is likely that multifactorial etiologies, with combined endocrine and metabolic abnormalities, have profound effects on body fat distribution and insulin resistance (10).

In HIV-positive patients with COPD who are receiving highly active antiretroviral therapy, clinical status and pulmonary function tests should be monitored. Nonprotease inhibitor antiretroviral combinations, such as those containing the nucleoside analogue stavudine, have also been associated with the lipodystrophy syndrome; therefore, patients on any antiretroviral combination require monitoring (10). Regression of the lipodystrophy syndrome after stopping or changing therapy has not been documented uniformly, but it may take eight weeks for abdominal girth to be measurably reduced (11).

REFERENCES
Submit your manuscripts at http://www.hindawi.com